癌灶CD4^+CD25^+和CD8^+ T细胞亚群与卵巢浆液性癌患者生存期相关  

Analysis in the number of CD4^+CD25^+ and CD8^+ T lymphocytes in ovarian serous carcinoma

作　　者：魏双燕[1] 姜洁[1] 南芳芳[2] 成磊[1] 

机构地区：[1]山东大学齐鲁医院妇产科,济南250012 [2]滨州医学院附属医院妇产科,滨州256603

出　　处：《现代免疫学》2008年第4期322-325,共4页Current Immunology

基　　金：国家自然科学基金资助项目(30672233)

摘　　要：检测卵巢浆液性癌患者癌组织中CD4+CD25+及CD8+T细胞的数目,探讨其两种T细胞介导的免疫功能对疾病发展及预后的影响。免疫组织化学双标及单标的染色方法检测41例卵巢浆液性癌患者手术切除癌组织标本中CD4+CD25+和CD8+T细胞的数目。结果显示,癌灶中CD4+CD25+T淋巴细胞为(19.95±11.50)个/10HPF,CD8+T淋巴细胞为(43.46±16.69)个/10HPF。生存分析发现高CD4+CD25+T细胞组患者总生存期较低CD4+CD25+T细胞组缩短,差异有显著性(P<0.05);而高CD8+T细胞组患者总生存期与低CD8+T细胞组相比延长,且差异有显著性(P<0.05),此外两种T细胞数目与患者年龄、病理分级、临床分期、腹水细胞学及淋巴结转移等临床病理因素均无关(P>0.05)。结果表明,卵巢浆液性癌中高CD4+CD25+T细胞提示患者预后不良,可能与CD4+CD25+T细胞介导的免疫抑制导致肿瘤免疫逃逸有关;癌组织中高CD8+T细胞提示患者预后较好,两种T细胞对卵巢浆液性癌预后的评估有重要的价值,同时可以通过阻断CD4+CD25+T细胞的免疫抑制作用改善卵巢浆液性癌患者的预后,为卵巢癌治疗提供靶目标。The number of CD4+CD25+ and CD8+ T lymphocytes in cancerous tissues of patients with ovarian serous carcinoma was analyzed in order to clarify the effect of immune function of these two varieties of immnue cells upon the disease progression and prognosis.In this study,the number of these immune cells in the operation specimens from 41 patients with ovarian serous carcinoma was determined by immunohistochemical technique with double-or single-labeled staining.It was demonstrated that the numbers of CD4+CD25+...

关 键 词：卵巢浆液性癌 CD4+CD25+T细胞 CD8+T细胞 

分 类 号：R737.31[医药卫生—肿瘤]